Guest writer Joanna Buoniconti says that new treatments have granted her many things she's grateful for, including the ...

Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma ...

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly dosing schedule.

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg ...

How many individuals have been treated with SPINRAZA worldwide? Over 14,000 individuals have been treated with SPINRAZA across more than 71 countries, spanning different ages and SMA types.

SPINRAZA has shown efficacy across ages and SMA types with a well-established safety profile based on data in patients treated up to 10 years, combined with unsurpassed real-world experience.

Biogen said salanersen uses the same mechanism of action as its Spinraza drug for SMA but is designed to achieve greater potency, giving it the potential to achieve high efficacy and enable once ...

Biogen said that new data examining of its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates that a higher dose than currently approved may lead to better ...

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews, but can it help return the drug to growth?